AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

[at noodls] – CAMBRIDGE, Mass. and TOKYO, Japan, November 28, 2012 — AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has accepted for … more

View todays social media effects on AVEO

View the latest stocks trending across Twitter. Click to view dashboard